New-Onset Inflammatory Bowel Diseases Among ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
New-Onset Inflammatory Bowel Diseases Among IL-17 inhibitors-Treated Patients: Results From The Case-Control MISSIL Study.
Auteur(s) :
Letarouilly, Jean-Guillaume [Auteur]
Service de rhumatologie[Lille]
Pham, Thao [Auteur]
Service de Rhumatologie [Hôpital de la Conception - APHM]
Aix Marseille Université [AMU]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Service de Biostatistiques [CHRU Lille]
Acquacalda, É. [Auteur]
Banneville, B. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Barbarot, S. [Auteur]
Physiopathologie des Adaptations Nutritionnelles [PhAN]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Baudart, P. [Auteur]
CHU Caen
Bauer, Élodie [Auteur]
Service de Rhumatologie [CHRU Nancy]
Claudepierre, P. [Auteur]
Service de rhumatologie [CHU Henri Mondor]
Epidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
Constantin, A. [Auteur]
Centre de Rhumatologie [CHU Toulouse]
Dernis, E. [Auteur]
Service de Rhumatologie [CH Le Mans]
Felten, R. [Auteur]
Service de rhumatologie [Strasbourg]
Gaudin, P. [Auteur]
Service de Rhumatologie [CHU de Grenoble]
Girard, C. [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Gombert, Bruno [Auteur]
Groupe hospitalier de La Rochelle
Goupille, P. [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Guennoc, Xavier [Auteur]
Henry-Desailly, I. [Auteur]
CHU Amiens-Picardie
Jullien, D. [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Karimova, Elena [Auteur]
Lanot, Sylvain [Auteur]
Centre Hospitalier Intercommunal Alençon-Mamers [CHICAM]
Le Dantec, Loïc [Auteur]
Pascart, Tristan [Auteur]
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Groupe Hospitalier de l'Institut Catholique de Lille [GHICL]
Plastaras, L. [Auteur]
Hôpitaux Civils de Colmar
Sultan, Nathalie [Auteur]
Centre Hospitalier Universitaire de La Réunion [CHU La Réunion]
Truchet, Xavier [Auteur]
Hopital d'instruction des armées Sainte-Anne [Toulon] [HIA]
Varin, S. [Auteur]
Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon [CHD Vendée]
Wendling, D. [Auteur]
Service de Rhumatologie
Epigénétique des infections virales et des maladies inflammatoires (UR 4266) [EPILAB]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Gaboriau, Louise [Auteur]
Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] [CRPV]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Peyrin-Biroulet, L. [Auteur]
Service d'Hépato-gastro-entérologie [CHRU Nancy]
Flipo, Rene-Marc [Auteur]
Service de rhumatologie[Lille]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Service de rhumatologie[Lille]
Pham, Thao [Auteur]
Service de Rhumatologie [Hôpital de la Conception - APHM]
Aix Marseille Université [AMU]
Pierache, Adeline [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Service de Biostatistiques [CHRU Lille]
Acquacalda, É. [Auteur]
Banneville, B. [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Barbarot, S. [Auteur]
Physiopathologie des Adaptations Nutritionnelles [PhAN]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Baudart, P. [Auteur]
CHU Caen
Bauer, Élodie [Auteur]
Service de Rhumatologie [CHRU Nancy]
Claudepierre, P. [Auteur]
Service de rhumatologie [CHU Henri Mondor]
Epidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
Constantin, A. [Auteur]
Centre de Rhumatologie [CHU Toulouse]
Dernis, E. [Auteur]
Service de Rhumatologie [CH Le Mans]
Felten, R. [Auteur]
Service de rhumatologie [Strasbourg]
Gaudin, P. [Auteur]
Service de Rhumatologie [CHU de Grenoble]
Girard, C. [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Gombert, Bruno [Auteur]
Groupe hospitalier de La Rochelle
Goupille, P. [Auteur]
Centre Hospitalier Régional Universitaire de Tours [CHRU Tours]
Guennoc, Xavier [Auteur]
Henry-Desailly, I. [Auteur]
CHU Amiens-Picardie
Jullien, D. [Auteur]
Hôpital Edouard Herriot [CHU - HCL]
Karimova, Elena [Auteur]
Lanot, Sylvain [Auteur]
Centre Hospitalier Intercommunal Alençon-Mamers [CHICAM]
Le Dantec, Loïc [Auteur]
Pascart, Tristan [Auteur]
Marrow Adiposity & Bone Lab (MABLab) - ULR 4490
Groupe Hospitalier de l'Institut Catholique de Lille [GHICL]
Plastaras, L. [Auteur]
Hôpitaux Civils de Colmar
Sultan, Nathalie [Auteur]
Centre Hospitalier Universitaire de La Réunion [CHU La Réunion]
Truchet, Xavier [Auteur]
Hopital d'instruction des armées Sainte-Anne [Toulon] [HIA]
Varin, S. [Auteur]
Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon [CHD Vendée]
Wendling, D. [Auteur]
Service de Rhumatologie
Epigénétique des infections virales et des maladies inflammatoires (UR 4266) [EPILAB]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Gaboriau, Louise [Auteur]
Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] [CRPV]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Peyrin-Biroulet, L. [Auteur]
Service d'Hépato-gastro-entérologie [CHRU Nancy]
Flipo, Rene-Marc [Auteur]
Service de rhumatologie[Lille]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Titre de la revue :
Rheumatology
Nom court de la revue :
Rheumatology (Oxford)
Date de publication :
2021-11-06
ISSN :
1462-0332
Mot(s)-clé(s) en anglais :
IBD
real-world
IL-17 inhibitor
secukinumab
spondyloarthritis
PsA
psoriasis
real-world
IL-17 inhibitor
secukinumab
spondyloarthritis
PsA
psoriasis
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Objectives
To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life.
Methods
A French national registry (MISSIL) ...
Lire la suite >Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.Lire moins >
Lire la suite >Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Date de dépôt :
2024-01-12T05:43:58Z
2024-02-29T09:27:34Z
2024-02-29T09:27:34Z
Fichiers
- keab819.pdf
- Version éditeur
- Accès libre
- Accéder au document